thalidomide has been researched along with Brain Ischemia in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Apremilast (APR) is a selective inhibitor of phosphodiesterase-4 involved in various neurological diseases, including stroke." | 5.72 | Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression. ( Cheng, Z; Meng, X; Wang, M, 2022) |
| "Thalidomide has shown protective effects in different models of ischemia/reperfusion damage." | 5.42 | Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. ( Farfán, DJ; Medrano, JÁN; Ortiz-Plata, A; Palencia, G; Sánchez, A; Sotelo, J; Trejo-Solís, C, 2015) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Apremilast (APR) is a selective inhibitor of phosphodiesterase-4 involved in various neurological diseases, including stroke." | 1.72 | Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression. ( Cheng, Z; Meng, X; Wang, M, 2022) |
| "Pomalidomide (POM) is a clinically available immunomodulatory and anti-inflammatory agent." | 1.51 | Pomalidomide Reduces Ischemic Brain Injury in Rodents. ( Chang, CF; Chen, KY; Chen, YH; Chiang, YH; de Cabo, R; Greig, NH; Hoffer, BJ; Kang, SJ; Lai, JH; Navas-Enamorado, I; Scerba, MT; Tsai, YR; Tweedie, D; Wu, JC, 2019) |
| "Thalidomide treatment significantly decreased the infarct volume and neurological deficits of MCAO/R rats." | 1.48 | The Neuroprotective Effect of Thalidomide against Ischemia through the Cereblon-mediated Repression of AMPK Activity. ( Asahi, T; Fujiwara, M; Hayashi, H; Sawamura, N; Takagi, N; Yamada, H; Yamada, M, 2018) |
| "Thalidomide has shown protective effects in different models of ischemia/reperfusion damage." | 1.42 | Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. ( Farfán, DJ; Medrano, JÁN; Ortiz-Plata, A; Palencia, G; Sánchez, A; Sotelo, J; Trejo-Solís, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Meng, X | 1 |
| Cheng, Z | 1 |
| Mohammed, RA | 1 |
| El-Yamany, MF | 1 |
| Abdel-Rahman, AA | 1 |
| Nassar, NN | 1 |
| Al-Shorbagy, MY | 1 |
| Sawamura, N | 1 |
| Yamada, M | 1 |
| Fujiwara, M | 1 |
| Yamada, H | 1 |
| Hayashi, H | 1 |
| Takagi, N | 1 |
| Asahi, T | 1 |
| Tsai, YR | 1 |
| Tweedie, D | 1 |
| Navas-Enamorado, I | 1 |
| Scerba, MT | 1 |
| Chang, CF | 1 |
| Lai, JH | 1 |
| Wu, JC | 1 |
| Chen, YH | 1 |
| Kang, SJ | 1 |
| Hoffer, BJ | 1 |
| de Cabo, R | 1 |
| Greig, NH | 1 |
| Chiang, YH | 1 |
| Chen, KY | 1 |
| Palencia, G | 1 |
| Medrano, JÁN | 1 |
| Ortiz-Plata, A | 1 |
| Farfán, DJ | 1 |
| Sotelo, J | 1 |
| Sánchez, A | 1 |
| Trejo-Solís, C | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 1 |
| Südhoff, T | 1 |
| Fenk, R | 1 |
| Straka, C | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Ostermann, H | 1 |
| Berdel, WE | 1 |
| Kienast, J | 1 |
1 trial available for thalidomide and Brain Ischemia
| Article | Year |
|---|---|
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem | 2003 |
5 other studies available for thalidomide and Brain Ischemia
| Article | Year |
|---|---|
Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Claudin-5; Cyclic Nucleotide Phosphodiesterases, Type | 2022 |
Role of pERK1/2-NFκB signaling in the neuroprotective effect of thalidomide against cerebral ischemia reperfusion injury in rats.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Disease Models, Animal; Hippocampus; Male; Memory | 2021 |
The Neuroprotective Effect of Thalidomide against Ischemia through the Cereblon-mediated Repression of AMPK Activity.
Topics: AMP-Activated Protein Kinases; Animals; ATP-Dependent Proteases; Brain Ischemia; Cell Death; Cell Li | 2018 |
Pomalidomide Reduces Ischemic Brain Injury in Rodents.
Topics: Angiogenesis Inhibitors; Animals; Brain Ischemia; Male; Mice; Rats; Thalidomide | 2019 |
Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Inflammation; M | 2015 |